11th Circ. AndroGel Decision Bolsters FTC Pay-For-Delay Case

Law360, New York (March 21, 2013, 6:06 PM EDT) -- The Eleventh Circuit on Thursday refused a bid by an Abbott Laboratories subsidiary to seal a proprietary financial analysis for its AndroGel drug, a decision that allows the Federal Trade Commission to use the document in its U.S. Supreme Court challenge to so-called pay-for-delay settlements.

The appeals court said U.S. District Judge Thomas W. Thrash Jr. hadn't abused his discretion when he unsealed a confidential document produced by Solvay Pharmaceuticals — now known as AbbVie Products LLC — revealing the benefits of a reverse settlement with...
To view the full article, register now.